KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Asset Writedowns and Impairment (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Asset Writedowns and Impairment for 12 consecutive years, with $40000.0 as the latest value for Q1 2026.

  • For Q1 2026, Asset Writedowns and Impairment fell 34.43% year-over-year to $40000.0; the TTM value through Mar 2026 reached $965000.0, down 67.4%, while the annual FY2025 figure was $986000.0, 67.48% down from the prior year.
  • Asset Writedowns and Impairment hit $40000.0 in Q1 2026 for Ionis Pharmaceuticals, down from $4.6 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $4.6 million in Q4 2025 and bottomed at -$3.9 million in Q3 2025.
  • Average Asset Writedowns and Impairment over 5 years is $465294.1, with a median of $256000.0 recorded in 2024.
  • Year-over-year, Asset Writedowns and Impairment surged 737.84% in 2024 and then crashed 735.48% in 2025.
  • Ionis Pharmaceuticals' Asset Writedowns and Impairment stood at $875000.0 in 2022, then increased by 11.2% to $973000.0 in 2023, then surged by 107.91% to $2.0 million in 2024, then skyrocketed by 128.82% to $4.6 million in 2025, then plummeted by 99.14% to $40000.0 in 2026.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods came in at $40000.0, $4.6 million, and -$3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.